- The FDA has expanded the label for Merck's (NYSE:MRK) Keytruda (pembrolizumab) to include adjuvant treatment of stage IIb or IIc melanoma following complete resection in patients 12 and older.
- Keytruda was already approved for unresectable or metastatic melanoma.
- Keytruda was approved earlier this week in Japan for esophageal carcinoma in combination with chemotherapy.
Merck's Keytruda approved as adjuvant therapy for stage IIb, IIc melanoma
Recommended For You
About MRK Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MRK | - | - |
Merck & Co., Inc. |